Avoro Capital Advisors LLC
NEW YORK, NY · Quarter end: Sep 30, 2026 · Filed with SEC: Nov 16, 2026 · Open the SEC source ↗
Portfolio Return (1Y)——
Portfolio Value (AUM)Total value of the fund's US stock portfolio reported to the SEC.$9.69B2026 Q3
Positions30
Top-10 ConcentrationPercent of the portfolio in the 10 largest holdings. High means the fund is concentrated in few stocks.83.3%
What Changed This Quarter?
Top Holdings
UTHR
United Therapeutics
15.4%
ASND
Ascendis Pharma A/S
11.9%
KRYS
Krystal Biotech
9.9%
ARGX
Argenx
9.9%
MDGL
Madrigal Pharmaceuticals
9.5%
KYMR
Kymera Therapeutics
8.6%
ARWR
Arrowhead Pharmaceuticals
7.4%
RVMD
Revolution Medicines
4.5%
New / Increased
5 new · 1 increased
DMRANEW
Damora Therapeutics
0.8%
ABVXNEW
Abivax
0.5%
SCTXNEW
Scribe Therapeutics
0.5%
BiohavenNEW
Biohaven
0.4%
BRVENEW
Braveheart Bio
0.3%
AVTX
Avalo Therapeutics
0.4%
+1.9%
Reduced / Exited
15 reduced · 1 sold out
CELC
Celcuity
1.2%
-55.9%
RVMD
Revolution Medicines
4.5%
-6.6%
ARWR
Arrowhead Pharmaceuticals
7.4%
-3.1%
ASND
Ascendis Pharma A/S
11.9%
-1.2%
UTHR
United Therapeutics
15.4%
-0.8%
Damora Therap…EXIT
Damora Therapeutics
0.9%
Read the 2026-Q2 quarterly report · 13F Filing Calendar
13F data shows quarter-end positions, is delayed by up to 45 days and covers only long positions in US-listed securities; short positions, most derivatives and non-US assets are not reported.